Zogenix and Battelle to Collaborate on Advanced Drug Delivery Technology
The companies have signed a Letter of Intent to enter into an exclusive co-marketing and technology development option agreement to utilize
In the joint marketing arrangement,
"We believe DosePro features market-leading technology for the safe and effective delivery of biologics, especially high viscosity formulations, which is critically important to our customers," Kunz said. "This collaboration will enhance our ability to extend our leadership in drug delivery technology development to create innovative solutions for the pharmaceutical industry."
As the world's largest independent research and development organization, Battelle provides innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management;
Battelle also is one of the nation's leading charitable trusts focusing on societal and economic impact and actively supporting and promoting science, technology, engineering and mathematics (STEM) education.
Forward Looking Statements
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and
1Hibbard, J and Turanin, J. (2011), Will Patients Accept and Adopt a Subcutaneous Self-injection Dosage Form When Alternative Oral or Nasal Dosage Forms Are Available? A Case Study in Needle-free Subcutaneous Delivery of Triptans for Migraine Headache; Poster Presentation, PDA Universe of Prefilled Syringes and Injection Devices,
SUMAVEL®, DosePro®, ReldayTM and ZohydroTM are trademarks of
CONTACT: ZOGENIX INVESTORS:
Zack Kubow| The Ruth Group646.536.7020 | email@example.com ZOGENIX MEDIA: Victoria Aguiar| The Ruth Group646.536.7013 | firstname.lastname@example.org BATTELLE: Katy Delaney614.424.7208 | email@example.com T.R. Massey614.424.5544 | firstname.lastname@example.org